Literature DB >> 26827841

Field application of immunoassays for the detection of Mycobacterium bovis infection in the African buffalo (Syncerus caffer).

E M D L van der Heijden1, A O Jenkins2, D V Cooper3, V P M G Rutten2, A L Michel4.   

Abstract

The African buffalo (Syncerus caffer) is considered the most important maintenance host of bovine tuberculosis (BTB) in wildlife in Southern Africa. The diagnosis of Mycobacterium bovis infection in this species mostly relies on the single intradermal comparative tuberculin test (SICTT). As an alternative, the BOVIGAM® 1G, an interferon-gamma (IFN-γ) release assay, is frequently used. The test performance of cell-mediated immunity (CMI-) and humoral immunity (HI-) based assays for the detection of M. bovis infections in buffaloes was compared to identify the test or test combination that provided the highest sensitivity in the study. Buffaloes were sampled during the annual BTB SICTT testing in the Hluhluwe-iMfolozi-Park (KwaZulu-Natal, South Africa) during June 2013. A total of 35 animals were subjected to the SICTT, 13 of these tested positive and one showed an inconclusive reaction. CMI-based assays (BOVIGAM® 1G (B1G) and BOVIGAM® 2G (B2G)) as well as a serological assay (IDEXX TB ELISA) were used to further investigate and compare immune responsiveness. Thirteen SICTT positive buffaloes and one inconclusive reactor were slaughtered and a post-mortem (PM) examination was conducted to confirm BTB. Lesions characteristic of BTB were found in 8/14 animals (57.1%). Test results of individual assays were compared with serial and parallel test interpretation and the sensitivity was calculated as a percentage of test positives out of the number of SICTT positive animals with granulomatous lesions (relative sensitivity). The B1G assay showed the highest individual sensitivity (100%; 8/8) followed by the B2G assay (75%; 6/8) and the IDEXX TB ELISA (37.5%; 3/8). Therefore, using in parallel interpretation, any combination with the B1G showed a sensitivity of 100% (8/8), whereas combinations with the B2G showed a 75% sensitivity (6/8). Out of the 21 SICTT negative animals, 7 animals showed responsiveness in the B2G or IDEXX TB ELISA. In conclusion, this study has shown that the BOVIGAM® IFN-γ assay had the highest test performance.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AFRICAN buffalo (Syncerus caffer); Bovine tuberculosis; Diagnostic test performance; Immunodiagnosis; Mycobacterium bovis

Mesh:

Substances:

Year:  2015        PMID: 26827841     DOI: 10.1016/j.vetimm.2015.12.003

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  4 in total

1.  TB Control in Humans and Animals in South Africa: A Perspective on Problems and Successes.

Authors:  Christina Meiring; Paul D van Helden; Wynand J Goosen
Journal:  Front Vet Sci       Date:  2018-11-27

Review 2.  Review of Diagnostic Tests for Detection of Mycobacterium bovis Infection in South African Wildlife.

Authors:  Netanya Bernitz; Tanya J Kerr; Wynand J Goosen; Josephine Chileshe; Roxanne L Higgitt; Eduard O Roos; Christina Meiring; Rachiel Gumbo; Candice de Waal; Charlene Clarke; Katrin Smith; Samantha Goldswain; Taschnica T Sylvester; Léanie Kleynhans; Anzaan Dippenaar; Peter E Buss; David V Cooper; Konstantin P Lyashchenko; Robin M Warren; Paul D van Helden; Sven D C Parsons; Michele A Miller
Journal:  Front Vet Sci       Date:  2021-01-28

Review 3.  Validation of laboratory tests for infectious diseases in wild mammals: review and recommendations.

Authors:  Beibei Jia; Axel Colling; David E Stallknecht; David Blehert; John Bingham; Beate Crossley; Debbie Eagles; Ian A Gardner
Journal:  J Vet Diagn Invest       Date:  2020-05-29       Impact factor: 1.279

Review 4.  Diagnosis of tuberculosis in wildlife: a systematic review.

Authors:  Jobin Thomas; Ana Balseiro; Christian Gortázar; María A Risalde
Journal:  Vet Res       Date:  2021-02-24       Impact factor: 3.683

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.